Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary D Novack
W Daniel Stamer

Showing results (31-40 of 550) with videos related to

Pageof 55
Sort By:
American Journal of Ophthalmology|February 5, 2003
Pupillary response to four concentrations of pilocarpine in normal subjectsGary D Novack
The Ocular Surface|April 10, 2012
How do drugs get their brand names?Gary D Novack
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|November 7, 2014
Eyes on new product developmentGary D Novack
The Ocular Surface|May 10, 2006
Research ethicsGary D Novack
The Ocular Surface|May 4, 2006
Risks and benefitsGary D Novack
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|October 19, 2023
Eyes on New Product DevelopmentGary D Novack
Ophthalmology|October 21, 2023
Infections from Over-the-Counter Artificial Tears: Implications for Patients and CliniciansGary D Novack
American Journal of Ophthalmology|January 16, 2025
Comment on: Subretinal Gene Therapy for Treatment of Retinal and Choroidal Vascular DiseasesGary D Novack
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|December 5, 2013
Eyes on new product developmentGary D Novack
The Ocular Surface|January 17, 2013
Quality of generic ophthalmic drugsGary D Novack
Pageof 55

Showing results (31-40 of 550) with videos related to

Sort By:
Pageof 55
American Journal of Ophthalmology|February 5, 2003
Pupillary response to four concentrations of pilocarpine in normal subjectsGary D Novack
The Ocular Surface|April 10, 2012
How do drugs get their brand names?Gary D Novack
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|November 7, 2014
Eyes on new product developmentGary D Novack
The Ocular Surface|May 10, 2006
Research ethicsGary D Novack
The Ocular Surface|May 4, 2006
Risks and benefitsGary D Novack
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|October 19, 2023
Eyes on New Product DevelopmentGary D Novack
Ophthalmology|October 21, 2023
Infections from Over-the-Counter Artificial Tears: Implications for Patients and CliniciansGary D Novack
American Journal of Ophthalmology|January 16, 2025
Comment on: Subretinal Gene Therapy for Treatment of Retinal and Choroidal Vascular DiseasesGary D Novack
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|December 5, 2013
Eyes on new product developmentGary D Novack
The Ocular Surface|January 17, 2013
Quality of generic ophthalmic drugsGary D Novack
Pageof 55